Impedimed (Australia) Performance
| IPD Stock | 0.05 0 2.00% |
Impedimed has a performance score of 3 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 0.59, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Impedimed's returns are expected to increase less than the market. However, during the bear market, the loss of holding Impedimed is expected to be smaller as well. Impedimed right now retains a risk of 4.48%. Please check out Impedimed jensen alpha, sortino ratio, maximum drawdown, as well as the relationship between the total risk alpha and treynor ratio , to decide if Impedimed will be following its current trending patterns.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Impedimed are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain fundamental indicators, Impedimed may actually be approaching a critical reversion point that can send shares even higher in December 2024. ...more
Last Split Factor 368:355 | Last Split Date 2020-04-03 |
1 | ImpediMed Limited Focuses on Commercial Growth Strategy - TipRanks | 11/18/2024 |
| Begin Period Cash Flow | 45.7 M |
Impedimed |
Impedimed Relative Risk vs. Return Landscape
If you would invest 4.80 in Impedimed on September 1, 2024 and sell it today you would earn a total of 0.30 from holding Impedimed or generate 6.25% return on investment over 90 days. Impedimed is generating 0.1866% of daily returns assuming 4.4805% volatility of returns over the 90 days investment horizon. Simply put, 39% of all stocks have less volatile historical return distribution than Impedimed, and 97% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Impedimed Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Impedimed's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Impedimed, and traders can use it to determine the average amount a Impedimed's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0417
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | IPD | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.48 actual daily | 39 61% of assets are more volatile |
Expected Return
| 0.19 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 3 97% of assets perform better |
Based on monthly moving average Impedimed is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Impedimed by adding it to a well-diversified portfolio.
Impedimed Fundamentals Growth
Impedimed Stock prices reflect investors' perceptions of the future prospects and financial health of Impedimed, and Impedimed fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Impedimed Stock performance.
| Return On Equity | -0.39 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (1.92) % | ||||
| Operating Margin | (2.01) % | ||||
| Current Valuation | 79.71 M | ||||
| Shares Outstanding | 2.02 B | ||||
| Price To Book | 2.53 X | ||||
| Price To Sales | 10.00 X | ||||
| Revenue | 10.32 M | ||||
| Gross Profit | 9.8 M | ||||
| EBITDA | (22.05 M) | ||||
| Net Income | (19.79 M) | ||||
| Cash And Equivalents | 13.55 M | ||||
| Total Debt | 1.14 M | ||||
| Book Value Per Share | 0.02 X | ||||
| Cash Flow From Operations | (17.79 M) | ||||
| Earnings Per Share | (0.01) X | ||||
| Total Asset | 46.99 M | ||||
| Retained Earnings | (330.95 M) | ||||
About Impedimed Performance
Assessing Impedimed's fundamental ratios provides investors with valuable insights into Impedimed's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Impedimed is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Impedimed is entity of Australia. It is traded as Stock on AU exchange.Things to note about Impedimed performance evaluation
Checking the ongoing alerts about Impedimed for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Impedimed help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Impedimed has some characteristics of a very speculative penny stock | |
| Impedimed had very high historical volatility over the last 90 days | |
| The company reported the revenue of 10.32 M. Net Loss for the year was (19.79 M) with profit before overhead, payroll, taxes, and interest of 9.8 M. | |
| Impedimed has accumulated about 13.55 M in cash with (17.79 M) of positive cash flow from operations. | |
| Latest headline from news.google.com: ImpediMed Limited Focuses on Commercial Growth Strategy - TipRanks |
- Analyzing Impedimed's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Impedimed's stock is overvalued or undervalued compared to its peers.
- Examining Impedimed's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Impedimed's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Impedimed's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Impedimed's stock. These opinions can provide insight into Impedimed's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Impedimed Stock Analysis
When running Impedimed's price analysis, check to measure Impedimed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Impedimed is operating at the current time. Most of Impedimed's value examination focuses on studying past and present price action to predict the probability of Impedimed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Impedimed's price. Additionally, you may evaluate how the addition of Impedimed to your portfolios can decrease your overall portfolio volatility.